Context Therapeutics (NASDAQ:CNTX – Get Free Report) was upgraded by Citizens Jmp to a “strong-buy” rating in a note issued ...

Shares of Context Therapeutics Inc. rose over 7% in Wednesday's pre-market trading after JMP Securities initiated coverage ...

Fintel reports that on January 8, 2025, JMP Securities initiated coverage of Context Therapeutics (NasdaqCM:CNTX) with a ...

Context Therapeutics (CNTX) has received a new Buy rating, initiated by JMP Securities analyst, Silvan Tuerkcan.Stay Ahead of the ...

D. Boral Capital has recently initiated Context Therapeutics Inc (CNTX) stock to Buy rating, as announced on November 25, 2024, according to Finviz. Analyst ratings are significant because they ...

CTIM-76 is under clinical development by Context Therapeutics and currently in Phase I for Ovarian Cancer. According to GlobalData, Phase I drugs for Ovarian Cancer have a 73% phase transition success ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Light Horse Therapeutics Inc., a developer of first-in-class small molecule therapeutics, announced a multi-target collaboration with Novartis to identify and develop potentially first-in-class ...

CTIM-76 is under clinical development by Context Therapeutics and currently in Phase I for Endometrial Cancer.